Human variability in hepatic and renal elimination: Implications for risk assessment

Journal of Applied Toxicology

Volumn 27, Issue 5, 2007, Pages 411-420

  Dorne, J L C M ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b EUROPEAN FOOD SAFETY AUTHORITY   (Italy)

Author keywords

Hepatic metabolism; Human variability; Pathway related uncertainty factors; Pharmacokinetics; Renal excretion; Risk assessment; Toxicokinetics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; GLYCINE; METHOXYCHLOR; SULFATE; XENOBIOTIC AGENT;

CARCINOGENICITY; CHEMICAL CARCINOGENESIS; ELDERLY CARE; ETHNIC DIFFERENCE; GENOTOXICITY; HUMAN; INTOXICATION; KIDNEY METABOLISM; LIVER METABOLISM; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOXICOKINETICS; URINARY EXCRETION;

AGE FACTORS; AGED; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INFANT, NEWBORN; KIDNEY; LIVER; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 34547894707     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1255     Document Type: Review

References (91)

1. Aranda JV, Turmen T, Sasyniuk BI. 1980. Pharmacokinetics of diuretics and methylxanthines in the neonate. Eur. J. Clin. Pharmacol. 18: 55-63.
2. Barlow SM, Greig JB, Bridges JW, Carere A, Carpy AJ, Galli CL, Kleiner J, Knudsen I, Koeter HB, Levy LS, Madsen C, Mayer S, Narbonne JF, Pfannkuch F, Prodanchuk MG, Smith MR, Steinberg P. 2002. Hazard identification by methods of animal-based toxicology. Food Chem. Toxicol. 40: 145-191.
3. Beck BD, Rudel R, Calabrese EJ. 1994. The use of toxicology in the regulatory process. In Principles and Methods of Toxicology, Wallace Hayes (ed.). Raven Press: New York.
4. Besunder JB, Reed MD, Blumer JL. 1988. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II). Clin. Pharmacokinet. 14: 261-286.
5. Brandon EF, Bosch TM, Deenen MJ, Levink R, van der Wal E, van Meerveld JB, Bijl M, Beijnen JH, Schellens JH, Meijerman I. 2006. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines. Toxicol. Appl. Pharmacol. 211: 1-10.
6. Buratti FM, Volpe MT, Meneguz A, Vittozzi L, Testai E. 2003. CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. Toxicol. Appl. Pharmacol. 186: 143-154.
7. Calabrese EJ. 1985. Uncertainty factors and interindividual variation. Regul. Toxicol. Pharmacol. 5: 190-196.
8. Cazeneuve C, Pons G, Rey E, Treluyer JM, Cresteil T, Thiroux G, D'Athis P, Olive G. 1994. Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. Br. J. Clin. Pharmacol. 37: 405-412.
9. Chen X, Wang L, Zhi L, Zhou G, Wang H, Zhang X, Hao B, Zhu Y, Cheng Z, He F. 2005. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin. Pharmacol. Ther. 78: 249-259.
10. Chiu WA, Barton HA, DeWoskin RS, Schlosser P, Thompson CM, Sonawane B, Lipscomb J, Krishnan K. 2007. Evaluation of physiologically based pharmacokinetic models for use in risk assessment. J. Appl. Toxicol. 27: 218-237.
11. Costa C, Catania S, Silvan V. 2003. [Genotoxicity and activation of organophosphate and carbamate pesticides by cytochrome P450 2D6]. G. Ital. Med. Lav. Ergon. 25 (Suppl): 81-82.
12. Costa LG. 2006. Current issues in organophosphate toxicology. Clin. Chim. Acta 366: 1-13.
13. Cresteil T. 1998. Onset of xenobiotic metabolism in children: toxicological implication. Food Addit. Contam. 15 (Suppl): 45-51.
14. Crump KS. 1984. A new method for determining allowable daily intakes. Fundam. Appl. Toxicol. 4: 854-871.
15. Cummins CL, Jacobsen W, Benet LZ. 2002. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300: 1036-1045.
16. Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 1998. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 63: 444-452.
17. Dalen P, Dahl ML, Eichelbaum M, Bertilsson L, Wilkinson GR. 1999. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 9: 697-706.
18. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. 1999. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin. Pharmacokinet. 36: 439-452.
19. Dorne JL. 2004. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. Fundam. Clin. Pharmacol. 18: 609-620.
20. Dorne JLCM, Ragas AMJ, Lokke HG. 2006. Harmonisation of uncertainty factors in human and ecological risk assessment. Toxicology 226: 75-76.
21. Dorne JLCM, Renwick AG. 2003. Prediction of human variability using kinetic data and Monte Carlo modelling for the derivation of pathway-related uncertainty factors for compounds handled by multiple pathways. Toxicol. Lett. 144: S195.
22. Dorne JL, Renwick AG. 2005. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol. Sci. 86: 20-26.
23. Dorne JL, Walton K, Renwick AG. 2001a. Human variability in glucuronidation in relation to uncertainty factors for risk assessment. Food Chem. Toxicol. 39: 1153-1173.
24. Dorne JL, Walton K, Renwick AG. 2001b. Uncertainty factors for chemical risk assessment, human variability in the pharmacokinetics of CYP1A2 probe substrates. Food Chem. Toxicol. 39: 681-696.
25. Dorne JL, Walton K, Renwick AG. 2003a. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem. Toxicol. 41: 201-224.
26. Dorne JL, Walton K, Renwick AG. 2003b. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. Food Chem. Toxicol. 41: 225-245.
27. Dorne JL, Walton K, Renwick AG. 2004a. Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation). Food Chem. Toxicol. 42: 397-421.
28. Dorne JL, Walton K, Renwick AG. 2004b. Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment. Food Chem. Toxicol. 42: 275-298.
29. Dorne JL, Walton K, Renwick AG. 2005. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem. Toxicol. 43: 203-216.
30. Dorne JL, Walton K, Slob W, Renwick AG. 2002. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food Chem. Toxicol. 40: 1633-1656.
31. Dourson M. 1996. Uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 24: 107.
32. Dourson ML, Felter S P, Robinson D. 1996. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 24: 108-120.
33. Dourson ML, Stara JF. 1983. Regulatory history and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 3: 224-238.
34. Dumas C, Loi CM, Cusack BJ. 1990. Hepatic drug metabolism and aging. Clin. Pharmacokinet. 19: 359-389.
35. Dybing E, Doe J, Groten J, Kleiner J, O'Brien J, Renwick AG, Schlatter J, Steinberg P, Tritscher A, Walker R, Younes M. 2002. Hazard characterisation of chemicals in food and diet, dose response, mechanisms and extrapolation issues. Food Chem. Toxicol. 40: 237-282.
36. Edler L, Poirier K, Dourson M, Kleiner J, Mileson B, Nordmann H, Renwick A, Slob W, Walton K, Wurtzen G. 2002. Mathematical modelling and quantitative methods. Food Chem. Toxicol. 40: 283-326.
37. Gentry PR, Hack CE, Haber L, Maier A, Clewell HJ 3rd. 2002. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicol. Sci. 70: 120-139.
38. Ginsberg G, Hattis D, Russ A, Sonawane B. 2005. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Environ. Health Perspect. 113: 1243-1249.
39. Ginsberg G, Hattis D, Sonawane B. 2004. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol. Appl. Pharmacol. 198: 164-183.
40. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Goble R. 2002. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 66: 185-200.
41. Gow PJ, Ghabrial H, Smallwood RA, Morgan DJ, Ching MS. 2001. Neonatal hepatic drug elimination. Pharmacol. Toxicol. 88: 3-15.
42. Hattis D. 1996. Human interindividual variability in susceptibility to toxic effects: from annoying detail to a central determinant of risk. Toxicology 111: 5-14.
43. Hattis D, Erdreich L, Ballew M. 1987. Human variability in susceptibility to toxic chemicals - a preliminary analysis of pharmacokinetic data from normal volunteers. Risk Anal. 7: 415-426.
44. Ito S, Gow R, Verjee Z, Giesbrecht E, Dodo H, Freedom R, Tonn GR, Axelson JE, Zalzstein E, Rosenberg HC, Koren G. 1998. Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response. J. Clin. Pharmacol. 38: 496-501.
45. Johnson JA. 2000. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int. J. Clin. Pharmacol. Ther. 38: 53-60.
46. Kirchheiner J, Brockmoller J. 2005. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77: 1-16.
47. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. 2004. Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. 308: 965-974.
48. Krishna DR, Shekar MS. 2005. Cytochrome P450 3A: genetic polymorphisms and inter-ethnic differences. Methods Find. Exp. Clin. Pharmacol. 27: 559-567.
49. Kroes R, Muller D, Lambe J, Lowik MR, van KJ, Kleiner J, Massey R, Mayer S, Urieta I, Verger P, Visconti A. 2002. Assessment of intake from the diet. Food Chem. Toxicol. 40: 327-385.
50. Land SJ, Zukowski K, Lee MS, Debiec-Rychter M, King CM, Wang CY. 1989. Metabolism of aromatic amines: relationships of N-acetylation, O-acetylation, N,O-acetyltransfer and deacetylation in human liver and urinary bladder. Carcinogenesis 10: 727-731.
51. Le Couteur DG, Hickey HM, Harvey PJ, McLean AJ. 1999. Oxidative injury reproduces age-related impairment of oxygen-dependent drug metabolism. Pharmacol. Toxicol. 85: 230-232.
52. LeBel M, Ferron L, Masson M, Pichette J, Carrier C. 1988. Benzyl alcohol metabolism and elimination in neonates. Dev. Pharmacol. Ther. 11: 347-356.
53. Leeder S, Adcock K, Gaedigk A, Gotschall R, Wilson JT, Kearns KL. 2000. Acquisition of CYP2D6 and CYP3A activities in the first year of life. Clin. Pharmacol. Ther. 67: 170.
54. Lehman AJ, Fitzhugh OG. 1954. 100-fold margin of safety. Assoc. Food Drug Off. U. S. Q. Bull. 18: 33-35.
55. Lin HJ, Han CY, Lin BK, Hardy S. 1993. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am. J. Hum. Genet. 52: 827-834.
56. Lindholm A, Welsh M, Alton C, Kahan BD. 1992. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin. Pharmacol. Ther. 52: 359-371.
57. Meek ME, Renwick A, Ohanian E, Dourson M, Lake B, Naumann BD, Vu V. 2002. Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. Toxicology 181-182: 115-120.
58. Miners JO, McKinnon RA, Mackenzie PI. 2002. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181-182: 453-456.
59. Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB. 2005. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5 6. Clin. Pharmacol. Ther. 78: 605-618.
60. Naumann BD, Silverman KC, Faria EC, Sargent EV. 2001. Case studies of categorical data-derived adjustment factors. Human Ecol. Risk Assess. 7: 61-105.
61. Naumann BD, Weidemann PA, Dixit R, Grossman SJ, Shen CF, Sargent EV. 1997. Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticals. Human Ecol. Risk Assess. 3: 355-365.
62. Nong A, McCarver DG, Hines RN, Krishnan K. 2006. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol. Appl. Pharmacol. 214: 78-87.
63. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. 1995. Factors affecting the absolute bioavailability of nifedipine. Br. J. Clin. Pharmacol. 40: 51-58.
64. Renwick AG. 1991. Safety factors and establishment of acceptable daily intakes. Food Addit. Contam. 8: 135-149.
65. Renwick AG. 1993. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit. Contam. 10: 275-305.
66. Renwick AG, Barlow SM, Hertz-Picciotto I, Boobis AR, Dybing E, Edler L, Eisenbrand G, Greig JB, Kleiner J, Lambe J, Muller DJ, Smith MR, Tritscher A, Tuijtelaars S, van den Brandt PA, Walker R, Kroes R. 2003. Risk characterisation of chemicals in food and diet. Food Chem. Toxicol. 41: 1211-1271.
67. Renwick AG, Dorne JL, Walton K. 2000. An analysis of the need for an additional uncertainty factor for infants and children. Regul. Toxicol. Pharmacol. 31: 286-296.
68. Renwick AG, Lazarus NR. 1998. Human variability and noncancer risk assessment - an analysis of the default uncertainty factor. Regul. Toxicol. Pharmacol. 27: 3-20.
69. Rose RL, Tang J, Choi J, Cao Y, Usmani A, Cherrington N, Hodgson E. 2005. Pesticide metabolism in humans, including polymorphisms. Scand. J. Work Environ. Health 31 (Suppl 1): 156-163.
70. Sams C, Cocker J, Lennard MS. 2004. Biotransformation of chlorpyrifos and diazinon by human liver microsomes and recombinant human cytochrome P450s (CYP). Xenobiotica 34: 861-873.
71. Sams C, Mason HJ, Rawbone R. 2000. Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. Toxicol. Lett. 116: 217-221.
72. Silverman KC, Naumann BD, Holder DJ, Dixit R, Faria EC, Sargent EV, Gallo MA. 1999 Establishing data-derived uncertainty factors from published pharmaceutical clinical trial data. Human Ecol. Risk Assess. 5: 1059-1090.
73. Slob W, Pieters MN. 1998. A probabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: general framework. Risk Anal. 18: 787-798.
74. Smith M. 2002. Food Safety in Europe (FOSIE): risk assessment of chemicals in food and diet: overall introduction. Food Chem. Toxicol. 40: 141-144.
75. Sonnier M, Cresteil T. 1998. Delayed ontogenesis of CYP1A2 in the human liver. Eur. J. Biochem. 251: 893-898.
76. Stresser DM, Kupfer D. 1998. Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-demethylation. Drug Metab. Dispos. 26: 868-874.
77. Suzuki H, Sugiyama Y. 2000. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 12: 3-12.
78. Swartout JC, Price PS, Dourson ML, Carlson-Lynch HL, Keenan RE. 1998. A probabilistic framework for the reference dose (probabilistic RfD). Risk Anal. 18: 271-282.
79. Tang J, Cao Y, Rose RL, Brimfield AA, Dai D, Goldstein JA, Hodgson E. 2001. Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab. Dispos. 29: 1201-1204.
80. Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T. 1997. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics 7: 441-452.
81. Truhaut R. 1991. The concept of the acceptable daily intake: an historical review. Food Addit. Contam. 8: 151-162.
82. U.S. EPA. 2002. A Review of the Reference Dose and Reference Concentration Processes. EPA/630/P-02/002F. December 2002. (PDF 2.8MB) available online at: http://www.epa.gov/iris/RFD_FINAL[1].pdf
83. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. 2001. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol. 41: 1149-1179.
84. Vermeire T, Stevenson H, Peiters MN, Rennen M, Slob W, Hakkert BC. 1999. Assessment factors for human health risk assessment: a discussion paper. Crit. Rev. Toxicol. 29: 439-490.
85. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13: 129-134.
86. Wedlund PJ. 2000. The CYP2C19 enzyme polymorphism. Pharmacology 61: 174-183.
87. WHO. 1987. Principles for the Safety Assessment of Food Additives and Contaminants in Food. Environmental Health Criteria 70. World Health Organization, International Programme on Chemical Safety: Geneva.
88. WHO. 1994. International Programme on Chemical Safety: Assessing Human Health Risks of Chemicals: Derivation of Guidance Values for Health-based Exposure Limits. Environmental Health Criteria 170. World Health Organization, International Programme on Chemical Safety: Geneva.
89. WHO. 1999. International Programme on Chemical Safety: Assessing Human Health Risks of Chemicals: Principles for the Assessment of Risk to Human Health from Exposure to Chemicals. Environmental Health Criteria 210. World Health Organization: Geneva.
90. WHO. 2001. International Programme on Chemical Safety: Guidance Document for the Use of Chemical-specific Adjustment Factors (CSAFs) for Interspecies Differences and Human Variability in Dose-concentration Response Assessment. World Health Organization: Geneva. http://www.ipcsharmonize.org/ CSAFsummary.htm
91. WHO. 2005. International Programme on Chemical Safety: Chemical-specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/concentration Response Assessment. World Health Organization: Geneva. http://www.who.int/ipcs/ methods/harmonization/areas/uncertainty/en/index.html